Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Public ClinicalTrials.gov record NCT06179303. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Study identification
- NCT ID
- NCT06179303
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- University of Washington
- Other
- Enrollment
- 60 participants
Conditions and interventions
Conditions
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Locally Advanced Unresectable HER2-Negative Breast Carcinoma
- Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma
- Metastatic HER2-Negative Breast Carcinoma
- Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions
- Abemaciclib Drug
- Anastrozole Drug
- Biospecimen Collection Procedure
- Computed Tomography Procedure
- Diagnostic Imaging Testing Procedure
- Exemestane Drug
- Fludeoxyglucose F-18 Other
- Fluorine F 18 Fluoro Furanyl Norprogesterone Drug
- Fulvestrant Drug
- Gonadotropin-releasing Hormone Analog Biological
- Letrozole Drug
- Positron Emission Tomography Procedure
- Tamoxifen Drug
- Therapeutic Estradiol Drug
Drug · Procedure · Other + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 21, 2024
- Primary completion
- Feb 28, 2027
- Completion
- May 31, 2028
- Last update posted
- Apr 15, 2026
2024 – 2028
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Siteman Cancer Center at Washington University | St Louis | Missouri | 63110 | Recruiting |
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06179303, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 15, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06179303 live on ClinicalTrials.gov.